Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis

Calopedos, Ross; Chalasani, Venu; Asher, Rebecca; Emmett, Louise; Woo, Henry H.

doi:10.1038/pcan.2017.23

Cited by 72 publications

(76 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our systematic review found a higher response rate for 177 Lu-PSMA RLT than the previous systematic review by Calopedos et al [ 16 ]. The difference may be due to differences in selection of articles.…”

Section: Discussioncontrasting

confidence: 75%

“…Furthermore, our systematic review evaluated the selection of articles with funnel plots, and included boxplots of the frequency of objective remission and overall survival as end-points for effect of the treatment. Anyway, both systematic review supported that 177 Lu-PSMA RLT is effective as treatment of mCRPC [ 16 ]. 177 Lu-PSMA-617 RLT and 177 Lu-PSMA I&T caused a best PSA decline of ≥50% more often and caused less adverse effects than 177 Lu-J591.…”

Section: Discussionmentioning

confidence: 99%

“…The reviewers undertook a similar search in Embase. We used previous systematic reviews as external validation of our literature searches [ 16 , 22 , 23 ]. A reviewer (FEvE) also undertook a manual search and also a search for ongoing studies in ClinicalTrials.gov .…”

Section: Search Strategymentioning

confidence: 99%

“…68 Ga-PSMA HBED-CC PET/CT detects sites of cancer lesions for most patients with mCRPC [ 14 , 15 ]. Patients with a positive 68 Ga-PSMA HBED-CC PET/CT might be treated with 177 Lu-PSMA radioligand therapy (RLT) [ 16 ]. 177 Lu-J591 is a macromolecular radiolabeled humanized monoclonal antibody that targets the extracellular part of PSMA.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review

Eyben

Roviello

Kiljunen

et al. 2017

Eur J Nucl Med Mol Imaging

156

View full text Add to dashboard Cite

AimsThere is a controversy as to the relative efficacy of 177Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether 177Lu-PSMA RLT and third-line treatment have similar effects and adverse effects (PROSPERO ID CRD42017067743).MethodsThe review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in Pubmed and Embase selected articles up to September 2017. A search in ClinicalTrials.gov indicated ongoing studies. The meta-analysis used the random-effects model.ResultsTwelve studies including 669 patients reported 177Lu-PSMA RLT. Overall, 43% of the patients had a maximum decline of PSA of ≥50% following treatment with 177Lu-PSMA RLT. The treatment with 177Lu-PSMA-617 and 177Lu-PSMA for imaging and therapy (I&T) had mainly transient adverse effects. Sixteen studies including 1338 patients reported third-line treatment. Overall, 21% of the patients had a best decline of PSA of ≥50% following third-line treatment. After third-line treatment with enzalutamide and cabazitaxel, adverse effects caused discontinuation of treatment for 10% to 23% of the patients. 177Lu-PSMA RLT gave a best PSA decline ≥50% more often than third-line treatment (mean 44% versus 22%, p = 0.0002, t test). 177Lu-PSMA RLT gave objective remission more often than third-line treatment (overall 31 of 109 patients versus 43 of 275 patients, p = 0.004, χ2 test). Median survival was longer after 177Lu-PSMA RLT than after third-line treatment, but the difference was not statistically significant (mean 14 months versus 12 months, p = 0.32, t test). Adverse effects caused discontinuation of treatment more often for third-line treatment than for 177Lu-PSMA RLT (22 of 66 patients versus 0 of 469 patients, p < 0.001, χ2 test).ConclusionsAs for patients with mCRPC, treatment with 177Lu-PSMA-617 RTL and 177Lu-PSMA I&T gave better effects and caused fewer adverse effects than third-line treatment.

show abstract

Section: Discussioncontrasting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Section: Search Strategymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review

Eyben

Roviello

Kiljunen

et al. 2017

Eur J Nucl Med Mol Imaging

156

View full text Add to dashboard Cite

show abstract

“…10. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis [11]. This review discusses novel PSMA tracers for imaging and radioimmunotherapy of men with recurrent prostate cancer, now in phase-3 trials.…”

Section: Non-metastatic Castration Resistant Prostate Can-mentioning

confidence: 99%